Approval Date: Aug 2022
For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week
Approval Date: Jul 2022
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Approval Date: Jul 2022
Indicated for the treatment of hypertension to lower blood pressure
Approval Date: Jul 2022
An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis
Approval Date: Jul 2022
Indicated for topical treatment of plaque psoriasis
Approval Date: Jul 2022
Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.
Approval Date: Jun 2022
Indicated for the treatment of partial-onset seizures.
Approval Date: Jun 2022
A biosimilar to Rituxan® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.
Approval Date: Jun 2022
Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Approval Date: May 2022
A steroid-free topical indicated for treatment of plaque psoriasis
